Page 16 - Bio Developments News Today

The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.

The Swiss biotech company Memo Therapeutics (MTx) has bagged CHF 25 million ($27.7 million) in a Series C round to finish the phase 2 development of its lead antibody treatment.

Kathryn Starzyk is an epidemiologist nad currently vice president of real-world evidence (RWE) at healthcare technology company, OM1.

In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.

Sarepta Therapeutics has hit a setback as its approved gene therapy Elevidys missed the primary goal of a phase 3 trial in children aged 4 through 7 years with the inherited disease Duchenne muscular dystrophy (DMD).

Peter Walters is a fellow of Advanced Therapies at CRB and has 20 years of experience specializing in pharmaceutical process and facility design. We spoke to him about CRB's latest life sciences report and best practices that must be adopted across the industry.

Triumvira Immunologics, a Texas-based clinical-stage company developing T cell therapeutics to treat patients with solid tumors, has announced that the first patient has been dosed in its phase 2 trial to treat gastric cancer.

In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.

We took the time to speak with Amy Walker, VP of research, at biotechnology company 4basebio to discuss if synthetic DNA templates represent the future of mRNA production.

Traditionally, the pharmaceutical landscape has been dominated by small molecules.